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In the United States, 12% of women are diagnosed with breast cancer in their
lifetime, and it is the second leading cause of cancer-related death in women.
Early detection and screening can improve the patient's life expectancy of 10
years on average. Unfortunately, breast cancer can be challenging to detect,
since it can appear anywhere in the breast tissue. Detecting the cancer before it
has progressed into aggressive stages can give patients more options and save
thousands of dollars in medical costs. Magnetic Resonance Imaging (MRI)
produces high quality images that can be used by Radiologists as a diagnostic
tool for breast cancer. Additionally, advances in Machine Learning technology
enable computers to learn from high-quality labeled datasets to achieve human-




The ResNet CNN accuracy score of about 98% between our training, testing,
and validation sets. After training it for 100 epochs we got an AUC score of
0.9986. This is the AUC for when positive is when someone survives within the 5
years. Then we also had an F1 score of 0.9980.
BreastNet is a model that contributes to both the medical field and data science.
In particular, some of the data preprocessing work can be valuable to other data
scientists who work on similar problems in biostatistics. The inclusion of a
program that is able to convert a DICOM format, which is highly isolated and
mostly used by the medical community alone, into the numpy format, can make
it easier for people who primarily manipulate python-native data formats.By
creating a network that directly manipulates 3D numpy arrays from directories,
BreastNet paves the way for general purpose computational intelligence to be
used to model 3 dimensional image data in a simple, straightforward way
BreastNet contributes to a growing body of studies that use machine learning to
help cancer patients understand their diagnosis and make informed treatment
decisions \cite{review}. By understanding whether they have a high or low risk of
death within the next five years, they will have agency to maximize their quality
of life. By focusing on specific results that patients find most important when
learning about their breast cancer diagnosis, BreastNet can help make a
positive impact on people’s lives; one that goes beyond the simple results the
program generates.
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The main goal of BreastNet is to predict the 5-year survival rate of breast
cancer patients. We use a Convolutional Neural Network (CNN) to predict
survival based on pre-processed MRI data, and a Recurrent Neural Network
(RNN) to predict survival based clinical data. By implementing dual models
based upon different data sources, we can create a robust classification system
that makes data-driven decisions based upon the most information possible.
We trained the CNN using 12254 sagittal slices from 340 MRI volumes for 222
patients, and we trained the RNN using a language-vector model with
vocabulary tokenization. Additionally, we employ methods such as stochastic
resampling to guard against class imbalance bias. We apply a disease-specific
survival censor to enable the models to use binary classification for each input
tensor. Since breast cancer is a disease that drastically affects people’s lives,
there is a great need for technology that can help patients make informed
decisions about the treatment plan they wish to pursue.
We used MRI images and Clinical Data from the ACRIN 6657 Clinical Trial,
which is publicly available on The Cancer Imaging Archive. We analyzed the
image data using a Convolutional Neural Network (CNN), and we analyzed the
clinical data using a fully connected Artificial Neural Network (ANN). We split
this data into a training, validation, and testing partitions. We used the data to
train the ResNet101 CNN model which then classified whether a patient in the
image was likely to survive or not after 5 years. We trained the network for 100
epochs on 90% of our dataset. Finally, 10% was used for cross-validation and
10% was used for testing were used from the dataset.
When patients are diagnosed with breast cancer, it is important for them to
understand how serious the disease is, and they rely on experts like doctors
and radiologists to interpret a wide range of medical data in their record, which
includes high quality images as well as clinical data and patient history. By
understanding the risk score of high and low risk, the patients are able to make
the right decisions about their future treatment plans. CNNs have the ability to
make use of medical images from a variety of sources to aid in the diagnosis
and prognosis of diseases like cancer. Since breast cancer is so common in
women, there are large publicly available datasets that contain a large number
of Magnetic Resonance Images (MRI). The I-SPY clinical trial was used to train
BreastNet, and it is a publicly available dataset which is available through The
Cancer Imaging Archive.
Fig.1-2 Two-dimensional Sagittal cross-sectional
images of the MRI scans from the I-SPY1 ACRIN
Clinical Trial, obtained from The Cancer Imaging
Archive
Materials and Methods
Fig.3-6 Top left: Loss function over each training
epoch. Bottom left: Accuracy function over each
training epoch. Top right: Confusion Matrix. Bottom
Right: Receiver Operating Curve, with AUC=0.9986
Fig.7 BreastNet architecture that makes use of the full
implementation of networks that accept clinical,
image, and genetic datasets since each sub-model is
specialized for each data type. This framework could
be used with ensemble learning techniques like
Boosting and Bagging
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